Lv4
480 积分 2024-04-26 加入
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
5天前
已完结
Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial
12天前
已完结
Evolving Trends in Surgically Managed Lung Cancer: A 16-Year Hospital-Based Epidemiological Analysis
18天前
已完结
Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes
24天前
已完结
Development and application of antibody-drug conjugates in gynecological cancers
26天前
已完结
Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis
1个月前
已完结
Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis
1个月前
已完结
Immune checkpoint inhibitor-related pneumonitis: From guidelines to the front lines
1个月前
已完结
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
1个月前
已完结
Real-world evidence of the efficacy of neoadjuvant pembrolizumab in triple-negative breast cancer: A surgeon's point of view
1个月前
已完结
皖公网安备34019202002308
